147 related articles for article (PubMed ID: 15116053)
21. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
22. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORC1 c.-1639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients.
Verde Z; Santiago C; Valle B; Fernández-Santander A; Bandrés F; Calvo E; Ruiz JR; Lucía A; Gallego FG
Thromb Haemost; 2009 Mar; 101(3):591-3. PubMed ID: 19277427
[No Abstract] [Full Text] [Related]
24. A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants.
Verde Z; Ruiz JR; Santiago C; Valle B; Bandrés F; Calvo E; Lucía A; Gómez Gallego F
PLoS One; 2010 Jun; 5(6):e11210. PubMed ID: 20585445
[TBL] [Abstract][Full Text] [Related]
25. Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin.
D'Ambrosio RL; D'Andrea G; Cappucci F; Chetta M; Di Perna P; Brancaccio V; Grandone E; Margaglione M
Haematologica; 2004 Dec; 89(12):1510-6. PubMed ID: 15590403
[TBL] [Abstract][Full Text] [Related]
26. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
[TBL] [Abstract][Full Text] [Related]
27. Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies.
Shintani M; Ieiri I; Inoue K; Mamiya K; Ninomiya H; Tashiro N; Higuchi S; Otsubo K
Clin Pharmacol Ther; 2001 Aug; 70(2):175-82. PubMed ID: 11503012
[TBL] [Abstract][Full Text] [Related]
28. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype.
van Dijk KN; Plat AW; van Dijk AA; Piersma-Wichers M; de Vries-Bots AM; Slomp J; de Jong-van den Berg LT; Brouwers JR
Thromb Haemost; 2004 Jan; 91(1):95-101. PubMed ID: 14691574
[TBL] [Abstract][Full Text] [Related]
29. A genome-wide association study of acenocoumarol maintenance dosage.
Teichert M; Eijgelsheim M; Rivadeneira F; Uitterlinden AG; van Schaik RH; Hofman A; De Smet PA; van Gelder T; Visser LE; Stricker BH
Hum Mol Genet; 2009 Oct; 18(19):3758-68. PubMed ID: 19578179
[TBL] [Abstract][Full Text] [Related]
30. The role of CYP2C9 gene polymorphisms on anticoagulant therapy after heart valve replacement.
Yildirim H; Tamer L; Sucu N; Atik U
Med Princ Pract; 2008; 17(6):464-7. PubMed ID: 18836275
[TBL] [Abstract][Full Text] [Related]
31. Impact of CYP2C9 genetic polymorphism on warfarin dose requirements in Pakistani population.
Siddiqi A; Khan DA; Khan FA; Naveed AK
Pak J Pharm Sci; 2010 Oct; 23(4):417-22. PubMed ID: 20884456
[TBL] [Abstract][Full Text] [Related]
32. Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response.
Nastasi-Catanese JA; Padilla-Gutiérrez JR; Valle Y; Ortega-Gutiérrez F; Gallegos-Arreola MP; Figuera LE
Genet Mol Res; 2013 Oct; 12(4):4413-21. PubMed ID: 24222221
[TBL] [Abstract][Full Text] [Related]
33. The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype.
Sandberg M; Johansson I; Christensen M; Rane A; Eliasson E
Drug Metab Dispos; 2004 May; 32(5):484-9. PubMed ID: 15100169
[TBL] [Abstract][Full Text] [Related]
34. Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants.
Schwarz UI; Stein CM
Clin Pharmacol Ther; 2006 Jul; 80(1):7-12. PubMed ID: 16815312
[No Abstract] [Full Text] [Related]
35. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
Thromb Haemost; 2004 Jul; 92(1):61-6. PubMed ID: 15213846
[TBL] [Abstract][Full Text] [Related]
36. Interindividual variability in sensitivity to warfarin--Nature or nurture?
Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
[TBL] [Abstract][Full Text] [Related]
37. Influence of CYP2C9 polymorphism and phenytoin co-administration on acenocoumarol dose in patients with cerebral venous thrombosis.
De T; Christopher R; Nagaraja D
Thromb Res; 2014 May; 133(5):729-35. PubMed ID: 24530212
[TBL] [Abstract][Full Text] [Related]
38. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
Visser LE; van Vliet M; van Schaik RH; Kasbergen AA; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
Pharmacogenetics; 2004 Jan; 14(1):27-33. PubMed ID: 15128048
[TBL] [Abstract][Full Text] [Related]
39. A multiplex assay to detect variations in the CYP2C9, VKORC1, CYP4F2 and APOE genes involved in acenocoumarol metabolism.
López-Parra AM; Borobia AM; Baeza C; Arroyo-Pardo E; Carcas AJ
Clin Biochem; 2013 Jan; 46(1-2):167-9. PubMed ID: 22917719
[TBL] [Abstract][Full Text] [Related]
40. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.
Vormfelde SV; Engelhardt S; Zirk A; Meineke I; Tuchen F; Kirchheiner J; Brockmöller J
Clin Pharmacol Ther; 2004 Dec; 76(6):557-66. PubMed ID: 15592327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
